ICPT - Why Is Rare Liver Disease Focused Intercept Pharmaceuticals Stock Trading Higher Today? | Benzinga
Italy-based Alfasigma has agreed to acquire Intercept Pharmaceuticals Inc (NASDAQ: ICPT) for $19.00 per share in cash.
The purchase price represents a premium of 82% to Intercept's closing stock price on September 25, 2023.
The anticipated transaction will materially expand Alfasigma's gastrointestinal and hepatology portfolio and its presence in the U.S. market.
Intercept's lead medicine is Ocaliva (obeticholic acid), a farnesoid X receptor agonist approved in ...